Abstract
The GES-2 β-lactamase is a class A carbapenemase, the emergence of which in clinically important bacterial pathogens is a disconcerting development as the enzyme confers resistance to carbapenem antibiotics. Tazobactam is a clinically used inhibitor of class A β-lactamases, which inhibits the GES-2 enzyme effectively, restoring susceptibility to β-lactam antibiotics. We have investigated the details of the mechanism of inhibition of the GES-2 enzyme by tazobactam. By the use of UV spectrometry, mass spectroscopy, and x-ray crystallography, we have documented and identified the involvement of a total of seven distinct GES-2-tazobactam complexes and one product of the hydrolysis of tazobactam that contribute to the inhibition profile. The x-ray structures for the GES-2 enzyme are for both the native (1.45 Å) and the inhibited complex with tazobactam (1.65 Å). This is the first such structure of a carbapenemase in complex with a clinically important β-lactam inhibitor, shedding light on the structural implications for the inhibition process. © 2011 by The American Society for Biochemistry and Molecular Biology, Inc.
Cite
CITATION STYLE
Frase, H., Smith, C. A., Toth, M., Champion, M. M., Mobashery, S., & Vakulenko, S. B. (2011). Identification of products of inhibition of GES-2 β-lactamase by tazobactam by X-ray crystallography and spectrometry. Journal of Biological Chemistry, 286(16), 14396–14409. https://doi.org/10.1074/jbc.M110.208744
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.